Site Search

Through our venture philanthropy model, we provide early stage funding to companies to develop breakthrough drugs for adults and children with cystic fibrosis.

Learn about our focus for 2020-2024 as we advance our path to a cure, meet emerging challenges in care, and explore new ways to partner with and support the CF community.

Engaging with biotechnology and pharmaceutical companies is essential to reaching our goal of a cure for all people with cystic fibrosis. These principles and standards for Industry interactions safeguard our independence, objectivity, and ability to make decisions that are in the best interest of people with CF.

As we look forward to 2018, our President and CEO, Preston W. Campbell, III, M.D., shares a special holiday message to the cystic fibrosis community.